Latest Kaiser Health News Stories
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Joanne Kenen of Politico and Margot Sanger-Katz of The New York Times discuss the health policy changes included in the just-concluded bipartisan budget deal on Capitol Hill. The panelists also talk about the final enrollment numbers for individual insurance purchased under the Affordable Care Act, and possible drug price proposals in President Donald Trump’s upcoming budget. Plus, Rovner interviews Andy Slavitt, who this week launched a health care advocacy group called “The United States of Care.”
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo and Julie Appleby and Sarah Jane Tribble of Kaiser Health News discuss President Donald Trump’s promises to reduce drug prices in his first State of the Union Address. The panelists also discuss the departure of the director of the Centers for Disease Control and Prevention after conflict-of-interest reports and the efforts by some states to flout the Affordable Care Act.
A KHN data analysis finds that the door of opportunities connecting Capitol Hill, the federal government and the drug industry likely spins in Big Pharma’s favor.
Southern Illinois University’s medical school has halted all herpes research, one of its most high-profile projects, amid growing controversy over a researcher’s unauthorized methods offshore and in the U.S.
“We really do have a lot of responsibility and culpability,” says one hospital official who is part of a working group trying to address the opioid epidemic. Patients have to expect more pain after surgery and understand the risk of addiction, says another doctor.
The lofty ideas floated and billion-dollar deals sealed at J.P. Morgan’s elite annual conference stand in stark contrast to the uncertainty that clouds health care outside its confines.
Orders for potassium iodide reportedly jumped after a Jan. 2 war of words between Trump and North Korea’s Kim Jong-un.
In this chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry’s agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.
Alex M. Azar II, the former president of the U.S. division of Eli Lilly, says the U.S. drug system encourages price increases — but he intends to work on that problem.
Fatalities are climbing in states that have been flooded by the deadly opioid fentanyl, but are remaining flat — or even falling — in many Western states, where the drug has not yet been as common as other parts of the country.
The Republican senator sent out letters to the Food and Drug Administration and HHS demanding an explanation about a rogue herpes vaccine trial.
This doctor came out of retirement with the goal of treating every patient at high risk for hepatitis C he encounters. The problem is finding them.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
Controversial research methods by university researcher unlikely to prompt federal response or institutional change, experts say.
Arizona is one of a few states that have declared the opioid epidemic a public health emergency. There’s no uniformity in what that means from state to state, though, and even within Arizona, there’s a wide divergence of opinion on how best to tackle the problem.
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.